Philip Tagari

Urinary Leukotriene E4 Concentrations Increase after Aspirin Challenge in Aspirin-sensitive Asthmatic Subjects

Pandora E. Christie, Philip Tagari, Anthony W. Ford‐Hutchinson et al. · American Review of Respiratory Disease · 1991 · 447 citations

Medicine, Internal Medicine, Pharmacology +9

The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor

Petpiboon Prasit, Z Wang, Christine Brideau et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 429 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9

Quinolines as potent 5-lipoxygenase inhibitors: Synthesis and biological profile of L-746,530

Daniel Dubé, Marc Blouin, Christine Brideau et al. · Bioorganic & Medicinal Chemistry Letters · 1998 · 272 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +11

Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation.

Melissa M. Carry, Victoria Korley, J T Willerson et al. · Circulation · 1992 · 172 citations · Full text

Medicine, Cardiology, Pharmacology +14

Morphological characterization of substance P‐like immunoreactive glomeruli in the superficial dorsal horn of the rat spinal cord and trigeminal subnucleus caudalis: A quantitative study

Alfredo Ribeiro‐da‐Silva, Philip Tagari, A. Claudio Cuello · The Journal of Comparative Neurology · 1989 · 136 citations

Medicine, Neurobiology, Neuroscience +17